Verteporfin injection
Products billed under this code include Visudyne.
Payment limit per 0.1 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Visudyne.
Payment limit per 0.1 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Visudyne | Bausch & Lomb Americas Inc. | 00187-5600-15 | 150 | $1,701.30 |
| Visudyne | Bausch & Lomb Americas Inc. | 24208-0560-15 | 150 | $1,701.30 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $11.342 | −$0.032 | 0.1 MG | Verteporfin injection | v1, posted September 17, 2026 |
| 3Q26 | $11.374 | −$0.20 | 0.1 MG | Verteporfin injection | v1, posted September 15, 2026 |
| 2Q26 | $11.574 | +$0.018 | 0.1 MG | Verteporfin injection | v1, posted September 15, 2026 |
| 1Q26 | $11.556 | +$0.018 | 0.1 MG | Verteporfin injection | v1, posted September 15, 2026 |
| 4Q25 | $11.538 | −$0.014 | 0.1 MG | Verteporfin injection | v1, posted September 8, 2026 |
| 3Q25 | $11.552 | +$0.033 | 0.1 MG | Verteporfin injection | v1, posted March 10, 2026 |
| 2Q25 | $11.519 | +$0.016 | 0.1 MG | Verteporfin injection | v1, posted March 10, 2026 |
| 1Q25 | $11.503 | −$0.031 | 0.1 MG | Verteporfin injection | v1, posted December 19, 2025 |
| 4Q24 | $11.534 | +$0.014 | 0.1 MG | Verteporfin injection | v1, posted June 11, 2025 |
| 3Q24 | $11.52 | +$0.079 | 0.1 MG | Verteporfin injection | v1, posted June 11, 2025 |
| 2Q24 | $11.441 | −$0.09 | 0.1 MG | Verteporfin injection | v1, posted March 11, 2025 |
| 1Q24 | $11.531 | +$0.294 | 0.1 MG | Verteporfin injection | v1, posted December 19, 2024 |
| 4Q23 | $11.237 | −$0.179 | 0.1 MG | Verteporfin injection | v1, posted October 10, 2024 |
| 3Q23 | $11.416 | +$0.041 | 0.1 MG | Verteporfin injection | v1, posted June 5, 2024 |
| 2Q23 | $11.375 | +$0.074 | 0.1 MG | Verteporfin injection | v1, posted February 23, 2024 |
| 1Q23 | $11.301 | −$0.222 | 0.1 MG | Verteporfin injection | v1, posted December 6, 2023 |
| 4Q22 | $11.523 | +$0.14 | 0.1 MG | Verteporfin injection | v1, posted June 22, 2023 |
| 3Q22 | $11.383 | +$0.148 | 0.1 MG | Verteporfin injection | v1, posted June 9, 2023 |
| 2Q22 | $11.235 | −$0.007 | 0.1 MG | Verteporfin injection | v1, posted December 14, 2022 |
| 1Q22 | $11.242 | −$0.01 | 0.1 MG | Verteporfin injection | v1, posted June 8, 2022 |
| 4Q21 | $11.252 | +$0.065 | 0.1 MG | Verteporfin injection | v1, posted June 2, 2022 |
| 3Q21 | $11.187 | −$0.067 | 0.1 MG | Verteporfin injection | v1, posted June 2, 2022 |
| 2Q21 | $11.254 | +$0.008 | 0.1 MG | Verteporfin injection | v1, posted March 1, 2022 |
| 1Q21 | $11.246 | – | 0.1 MG | Verteporfin injection | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.